Evidence map›Paper›PMID 31297545›Full record

ArticleHerz2019

Pulmonary and cardiac drugs: clinically relevant interactions.

H Olschewski, M Canepa, G Kovacs

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Herz, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

H OlschewskiDivision of Pulmonology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. horst.olschewski@medunigraz.at.
M CanepaCardiovascular Unit, Department of Internal Medicine, University of Genova, Genova, Italy.
G KovacsDivision of Pulmonology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Medical University of Graz · ATUniversity of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic heart and lung diseases are very common in the elderly population. The combination of chronic heart failure and chronic obstructive pulmonary disease (COPD) is also common and, according to current guidelines, these patients should be treated for both diseases. In patients with heart failure, beta-blockers are very important drugs because their use is associated with significantly improved morbidity and mortality. These beneficial effects were documented in patients with and without COPD, although theoretically there is a risk for bronchoconstriction, particularly with non-beta

Indexed as

Adrenergic beta-2 Receptor AgonistsMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesAgedDrug InteractionsHumansQuality of LifeAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsMuscarinic AntagonistsBeta-adrenergic blockersChronic obstructive pulmonary diseaseDrug side effectsHeart failureSympathomimetic drugs

Identifiers

PMID31297545
PMCPMC6726702
OpenAlexW2959017392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.